Provided by Tiger Fintech (Singapore) Pte. Ltd.

Biofrontera Inc

0.9460
+0.05706.41%
Volume:61.33K
Turnover:57.42K
Market Cap:10.09M
PE:-0.45
High:0.9690
Open:0.8900
Low:0.8810
Close:0.8890
52wk High:2.22
52wk Low:0.5360
Shares:10.67M
Float Shares:7.95M
Volume Ratio:1.58
T/O Rate:0.77%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1025
EPS(LYR):-3.2193
ROE:-531.54%
ROA:-48.85%
PB:-2.16
PE(LYR):-0.29

Loading ...

Biofrontera Q1 EPS $(0.47) Misses $(0.21) Estimate, Sales $8.59M Miss $10.55M Estimate

Benzinga
·
May 16

BRIEF-Biofrontera Announces New Patent Protection On Ameluz Until 2043

Reuters
·
May 16

Biofrontera's Revised Ameluz Formulation Receives US Patent Approval

MT Newswires Live
·
May 16

Biofrontera Inc. Faces Nasdaq Delisting Threat Due to Non-Compliance with Minimum Bid Price Rule

Reuters
·
May 15

Biofrontera Inc expected to post a loss of 21 cents a share - Earnings Preview

Reuters
·
May 14

Biofrontera AG’s Earnings Call Highlights Growth and Strategic Advances

TIPRANKS
·
Apr 24

Biofrontera AG Prepares to Release 2024 Financial Report

TIPRANKS
·
Apr 17

Biofrontera AG Reports 2024 Financial Results and Strategic Growth Plans

TIPRANKS
·
Apr 15

Biofrontera AG Meets 2024 Forecasts and Outlines 2025 Financial Expectations

TIPRANKS
·
Apr 15

Biofrontera’s Growth Potential: Buy Rating Backed by FDA Approval and Positive Phase 3 Results

TIPRANKS
·
Mar 25

Biofrontera Inc. Reports Record Sales and Strategic Advances

TIPRANKS
·
Mar 25

Biofrontera Full Year 2024 Earnings: Misses Expectations

Simply Wall St.
·
Mar 22

Biofrontera Inc (BFRI) Q4 2024 Earnings Call Highlights: Record Revenue Growth Amidst Financial ...

GuruFocus.com
·
Mar 22

Q4 2024 Biofrontera Inc Earnings Call

Thomson Reuters StreetEvents
·
Mar 22

Biofrontera Inc. Reports Record Revenue Growth in 2024

TIPRANKS
·
Mar 22

Biofrontera Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 21

Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update

GlobeNewswire
·
Mar 21

Biofrontera FY 2024 GAAP EPS $(3.22) May Not Be Comparable To $(0.85) Estimate, Sales $37.32M Miss $47.06M Estimate

Benzinga
·
Mar 21

Biofrontera Inc expected to post a loss of 2 cents a share - Earnings Preview

Reuters
·
Mar 19

Biofrontera Completes Patient Enrollment for Phase 3 Trial of Ameluz in Actinic Keratoses

MT Newswires Live
·
Mar 18